Amarillo Biosciences (AMAR) Issues Quarterly Earnings Results

Amarillo Biosciences (OTCMKTS:AMAR) issued its quarterly earnings results on Monday, November 20th. The company reported ($0.01) EPS for the quarter, Bloomberg Earnings reports.

Amarillo Biosciences (OTCMKTS:AMAR) remained flat at $$0.26 during trading hours on Thursday. The company had a trading volume of 189 shares, compared to its average volume of 2,066. Amarillo Biosciences has a 1 year low of $0.16 and a 1 year high of $0.30.

In other news, CEO Stephen T. Chen bought 203,000 shares of Amarillo Biosciences stock in a transaction on Monday, November 13th. The shares were bought at an average price of $0.19 per share, with a total value of $38,570.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders have acquired 219,000 shares of company stock worth $42,800.

COPYRIGHT VIOLATION WARNING: This article was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2017/12/07/amarillo-biosciences-inc-amar-releases-earnings-results.html.

Amarillo Biosciences Company Profile

Amarillo Biosciences, Inc is engaged in the business of biopharmaceutical research and development. The Company develops biologics for the treatment of human and animal diseases. The Company’s focus is research aimed at the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia and other indications using natural human interferon alpha that is administered in a low dose oral form.

Receive News & Ratings for Amarillo Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarillo Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply